Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.192,14
-1,10%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Better Therapeutics Inc (BTTX) Better Therapeutics Inc (BTTX) Notizie

BTTX

Better Therapeutics (BTTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BTTX
DataOraFonteTitoloSimboloCompagnia
14/03/202414:38Business WireBetter Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from NasdaqNASDAQ:BTTXBetter Therapeutics Inc
11/03/202414:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTTXBetter Therapeutics Inc
05/03/202415:25Business WireBetter Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health CentersNASDAQ:BTTXBetter Therapeutics Inc
04/03/202415:25Business WireBetter Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)NASDAQ:BTTXBetter Therapeutics Inc
01/03/202412:08Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:BTTXBetter Therapeutics Inc
20/02/202415:25Business WireBetter Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver DiseaseNASDAQ:BTTXBetter Therapeutics Inc
12/02/202422:28Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:BTTXBetter Therapeutics Inc
06/02/202415:43Business WireBetter Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes TreatmentNASDAQ:BTTXBetter Therapeutics Inc
06/02/202415:02Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:BTTXBetter Therapeutics Inc
23/01/202423:22Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:BTTXBetter Therapeutics Inc
17/01/202415:28Business WireBetter Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care AloneNASDAQ:BTTXBetter Therapeutics Inc
10/01/202413:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:BTTXBetter Therapeutics Inc
04/01/202420:00Business WireBetter Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United StatesNASDAQ:BTTXBetter Therapeutics Inc
02/01/202413:45Business WireBetter Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver DiseaseNASDAQ:BTTXBetter Therapeutics Inc
28/12/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BTTXBetter Therapeutics Inc
20/12/202323:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTTXBetter Therapeutics Inc
13/12/202323:24Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:BTTXBetter Therapeutics Inc
08/12/202302:09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BTTXBetter Therapeutics Inc
28/11/202313:45Business WireBetter Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost ReductionsNASDAQ:BTTXBetter Therapeutics Inc
14/11/202313:00Business WireFrost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership AwardNASDAQ:BTTXBetter Therapeutics Inc
09/11/202313:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BTTXBetter Therapeutics Inc
09/11/202313:00Business WireBetter Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:BTTXBetter Therapeutics Inc
08/11/202313:30Business WireBetter Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023NASDAQ:BTTXBetter Therapeutics Inc
26/10/202313:55Business WireBetter Therapeutics to Participate in the American College of Lifestyle Medicine’s 2023 Annual ConferenceNASDAQ:BTTXBetter Therapeutics Inc
16/10/202313:55Business WireBetter Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 DiabetesNASDAQ:BTTXBetter Therapeutics Inc
16/10/202313:22Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:BTTXBetter Therapeutics Inc
12/10/202322:17Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:BTTXBetter Therapeutics Inc
11/10/202313:55Business WireBetter Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 DiabetesNASDAQ:BTTXBetter Therapeutics Inc
06/10/202322:15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:BTTXBetter Therapeutics Inc
05/10/202313:45Business WireBetter Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep AdvancesNASDAQ:BTTXBetter Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BTTX

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
TIT
Telecom Italia
BIT
SPM
Saipem
BIT
SRG
Snam
BIT
TEN
Tenaris
BIT
TRN
Terna Trasmissione Elett...
BIT
IVG
Iveco Group NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network